

## REFERENCES

- 1- Abess, A.; Keel, D.M. and Graham, B.S. (2003):**  
Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris.  
Arch. Dermatol., 139:337-339.
- 2- Absalon, M.J.; Kozarich, J.W. and Stubbe, J. (1995):**  
Sequence-specific double-strand cleavage of DNA by Fe-bleomycin. The detection of sequence-specific double-strand breaks using hairpin oligonucleotides.  
Biochemistry, 34:2065-2075.
- 3- Adoue, D. and Arlet, P. (1984):**  
Bleomycin and Raynaud's phenomenon  
Ann. Intern. Med., 100: 770.
- 4- Aiba, S.; Rokugo, M. and Tagami, H. (1986):**  
Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts.  
Cancer, 58:1246-1251.
- 5- Akieida, G.J. (1975):**  
5-fluorouracil in the treatment of common warts of the hands.  
Br. J. Dermatol., 92:89-91.
- 6- Allen, A.L. and Fosko, S.W. (1998):**  
Lymphangitis as a complication of intralesional bleomycin therapy.  
J. Am. Acad. Dermatol., 120:963-964.
- 7- Amer, M.; Diab, N.; Ramadan, A.; Galal, A. and Salem, A. (1988):**  
Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts.  
J. Am. Acad. Dermatol., 18:1313-1316.

**8- Antonsson, A. and Hansson, B.G. (2002):**

Healthy skin of many animal species harbors papillomaviruses which are closely related to their human counterparts.  
J. Virol., 76:12537-12542.

**9- Arany, I. and Tyring, S.K. (1996):**

Status of local cellular immunity in interferon-responsive and non-responsive human papillomavirus-associated lesions.  
Sex. Transm. Dis. 23: 475-480.

**10- Arany, I.; Goel, A. and Tyring, S.K. (1995):**

Interferon response depends on viral transcription in human papillomavirus-containing lesions.  
Anticancer Res., 15:2865-2869.

**11- Aviles, A.; Maqueo, J.C.; Talavera, A.; Guzman, R. and Garcia, E.L. (1991):**

Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children.  
Am. J. Hematol., 36:243-248.

**12- Barland S.J.; Caumes, E.; Ankri, A.; Frances, C.; Katlama, C. and Chosidow, O. (1998):**

Bleomycin-induced digital gangrene.  
Eur. J. Dermatol., 8: 221-222.

**13- Bauman, C.; Francis, J.S.; Vanderhooft, S. and Sybert, V.P. (1996):**

Cimetidine therapy for multiple viral warts in children.  
J. Am. Acad. Dermatol., 35:271-272.

**14- Berkhout, R.J.; Bouwes, J.N. and Schegget, J. (2000):**

Persistence of human papillomavirus DNA in benign and premalignant skin lesions from renal transplant recipients.  
J. Clin. Microbiol., 38:2087-2096.

**15- Berman, A.; Domnitz, J.M. and Winkelmann, R.K. (1987):**

Plantar warts recently turned black.  
Arch. Dermatol., 118:47-51.

- 16- Berth-Jones, J. and Hutchinson, P.E. (1992):**  
Modern treatments of warts: cure rates at 3 and 6 months.  
Br. J. Dermatol., 127:262-264.
- 17- Beutner, K.R.; Becker, T.M. and Stone, K.M. (1991):**  
Epidemiology of human papillomavirus infections.  
Dermatologic Clinics, 9:211-218.
- 18- Braun, I.; Durst, M.; Mikumo, R.; Crowley, A. and Robinson, M. (1992):**  
Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection.  
Mol. Carcinog., 6:100-111.
- 19- Bremner, R.M. (1976):**  
Treatment with intralesional bleomycin.  
Cutis., 18:264-266.
- 20- Brodell, R.T. and Bredle, D.L. (1995):**  
The treatment of palmar and plantar warts using natural alpha interferon and a needleless injector.  
Dermatol. Surg., 21:213-218.
- 21- Brömme, D.; Rossi, A.B.; Smeekens, S.P.; Anderson, D.C.; and Payan, D.G. (1996):**  
Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization.  
Biochemistry, 35:6706-6714.
- 22- Brown, T.A.; Bouchard, T.; John, T.S.; Wayner, E. and Carter, W.G. (1991):**  
Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons.  
J. Cell. Biol., 113: 207-221.

- 23- Bunn, P.J.; Hoffman, S. and Norris, D. (1994):**  
Systemic therapy of cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome)  
Ann. Intern. Med., 121: 592-602.
- 24- Bunney, M.H.; Nolan, M.W.; Buxton, P.K.; Goings, S.M. and Prescott, R.J. (1984):**  
The treatment of resistant warts with intralesional bleomycin: a controlled clinical trial.  
Br. J. Dermatol., 110:197-207.
- 25- Campbell, M.J. and Machin, D. (1993):**  
Medical statistics, a common sense approach. Wiley, J. and S. (eds).  
New York, pp. 266.
- 26- Carr, J. and Gyorfi, T. (2000):**  
Human papillomavirus. Epidemiology, transmission, and pathogenesis.  
Clin. Lab. Med., 20:235-255.
- 27- Caumes, E.; Guernonprez, G.; Katlama, C. and Gentilini, M. (1992):**  
AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin.  
AIDS, 6:1483-1487.
- 28- Chan, S.Y.; Delius, H.; Halpern, A.L. and Bernard, H.U. (1995):**  
Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.  
J. Virol., 69:3074-3083.
- 29- Choi, Y.S.; Hann, S.K. and Park, Y. (1993):**  
The effect of cimetidine on verruca plana juvenilis: clinical trials in six patients.  
J. Dermatol., 20:497-500.
- 30- Cobb, M.W. (1990):**  
Human papillomavirus infection.  
J. Am. Acad. Dermatol., 20:547-566.

- 31- Coleman, N.; Birley, H.D.; Renton, A.M.; Hanna, N.F.; Ryait, B.K.; Byrne, M.; Taylor, R.D. and Stanley, M.A. (1994):**  
Immunological events in regressing genital warts.  
*Am. J. Clin. Pathol.*, 102:768-774.
- 32- Coleman, N. and Stanley, M.A. (1994):**  
Characterization and functional analysis of the expression of vascular adhesion molecules in human papillomavirus-related disease of the cervix.  
*Cancer*, 74:884-892.
- 33- Comis, R.L. (1992):**  
Bleomycin pulmonary toxicity: current status and future directions.  
*Semin. Oncol.*, 19:64-70.
- 34- Cooper, K.D.; Androphy, E.J.; Lowy, D. and Katz, S.I. (1990):**  
Antigen presentation and T-cell activation in epidermodysplasia verruciformis.  
*J. Investig. Dermatol.*, 94:769-776.
- 35- Cordero A.A.; Gaglielmi, H.A. and Woscoff, A. (1980):**  
The common warts: intralesional treatment with bleomycin sulfate.  
*Cutis*, 26:319-324.
- 36- Dalton B.M. and Halvachs, F.J. (1990):**  
Update on room-temperature stability of drug products labeled for refrigerated storage.  
*Am. J. Hosp. Pharm.*, 47:2522-2524.
- 37- De Bersaques, J. (1975):**  
Vitamin A acid in the topical treatment of warts.  
*Acta. Derm. Venereol. Suppl. (Stockh.)*, 74:169-170.
- 38- DeGrendele, H.C.; Estess, P. and Siegelman, M.H. (1997):**  
Requirement for CD44 in activated T cell extravasation into an inflammatory site.  
*Science*, 278: 672-675.

- 39- Del Mistro, a. and Bianchi, C. (2001):**  
HPV-related neoplasias in HIV-infected individuals.  
Eur. J. Cancer, 37: 1227-1235.
- 40- De Marco, F. and Marcante, M.L. (1995):**  
Cellular and molecular analyses of interferon beta cytopathic effect  
on HPV-16 in vitro transformed human keratinocytes (HPK-IA).  
J. Biol. Regul. Homeost. Agents, 9:24-30.
- 41- De Villers, E.M. (1994):**  
Human pathogenic papillomavirus types: an update. In: zur Hausen,  
H. (ed.): Human Pathogenic Papillomaviruses. Heidelberg,  
Springer, pp. I.
- 42- Dorr, R.T. and Von-Hoff D.D. (1994):**  
Drug monographs. In: Dorr, R. and Von-Hoff D. (eds): Cancer  
chemotherapy handbook. 2<sup>nd</sup> edition. Norwalk, Appleton and  
Lange, pp. 227.
- 43- Duthie, D.A. and McCallum, D.I. (1951):**  
Treatment of plantar warts with elastoplast and podophyllin.  
Br. J. Dermatol., 2:216-218.
- 44- Dyall-Smith, D.; Trowell, H. and Dyall-Smith, M.L. (1991):**  
Benign human papillomavirus infection in renal transplant  
recipients.  
Int. J. Dermatol., 30:785-789.
- 45- Egawa, K. (1994):**  
New types of human papillomaviruses and intracytoplasmic  
inclusion bodies: a classification of inclusion warts according to  
clinical features, histology, and associated HPV types.  
Br. J. Dermatol., 130:158-166.
- 46- Egawa, K.; Iftner, A. and Doorbar, J. (2000):**  
Synthesis of viral DNA and late capsid protein L1 in parabasal  
spinous cell layers of naturally occurring benign warts infected with  
human papillomavirus type 1.  
Virology, 268:281-293.

- 47- Esterowitz, D.; Greer, K.E.; Cooper, P.H. and Edlich, R.F. (1995):**  
Plantar warts in the athlete.  
Am. J. Emerg. Med., 13:441-443.
- 48- Ewin, D.M. (1992):**  
Hypnotherapy for warts (verruca vulgaris): 41 consecutive cases with 33 cures.  
Am. J. Clin. Hypn., 35:1-10.
- 49- Faessler, R. and Krebs, A. (1974):**  
Long-term reexamination of plantar warts treated by roentgen therapy.  
Dermatologica, 148:345-352.
- 50- Ferenczy, A.; Mitao, M. and Nagai, N. (1985):**  
Latent papillomavirus and recurring genital warts.  
N. Engl. J. Med., 313:784-788.
- 51- Frazer, I.H.; Thomas, R.; Zhou, J.; Leggatt, G.R.; Dunn, L.; McMillan, N.; Tindle, R.W.; Filgueira, L.; Manders, P.; Barnard, P. and Sharkey, M. (1999):**  
Potential strategies utilised by papillomavirus to evade host immunity.  
Immunol. Rev., 168:131-142.
- 52- Fujita, K. (1970):**  
Report on the treatment of verrucosis with local injection of bleomycin.  
Nishinihon. J. Dermatol., 38:445-453.
- 53- Galloway, D.A. (1994):**  
Papillomavirus capsids: a new approach to identify serological markers of HPV infection.  
J. Natl. Cancer Inst., 86:474-475.
- 54- Gershenson, D.M. (1988):**  
Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors.  
J. Clin. Oncol., 6: 270-274.

- 55- Gibbs, S.; Harvey, I.; Sterling, J. and Stark, R. (2002):**  
Local treatments for cutaneous warts: systematic review.  
Br. J. Dermatol., 31:325-461.
- 56- Gibson, J.R. (1988):**  
The treatment of viral warts with interferons.  
J. Antimicrob. Chemother., 21:391-393.
- 57- Giroglou, T.; Florin, L. and Schafer, F. (2001):**  
Human papillomavirus infection requires cell surface heparan sulfate.  
J. Virol., 75:1565-1570.
- 58- Glass, A.T. and Solomon, B.A. (1996):**  
Cimetidine therapy for recalcitrant warts in adults.  
Arch. Dermatol., 132:680-682.
- 59- Goldberg, R. (1997):**  
The war on warts: an update.  
Canadian Footcare Practice, 2:21-23.
- 60- Goldschmidt, H. and Kligman, A.M. (1958):**  
Experimental inoculation of humans with ectodermotropic viruses.  
J. Invest. Dermatol., 31:175-182.
- 61- Gonzalez, F.U.; Martinez, A.A.; Rodriguez, P.G. and Garcia-Perez, A. (1986):**  
Cutaneous toxicity of intralesional bleomycin administration in the treatment of periungual warts.  
Arch. Dermatol., 122:974-975.
- 62- Goodheart, H.P. (2000):**  
Superficial viral infections. Part 1: diagnosis of nongenital warts (verrucae).  
Women Health Primary Care, 3:729-732.
- 63- Greenstone, H.L.; Neiland, J.D. and de Visser, K.E. (1998):**  
Chimeric papillomavirus-like particle elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.  
Proc. Natl. Acad. Sci. USA, 95:1800-1805.
-

- 64- Hagensee, M.E., Olson, N.H.; Baker, T.S. and Galloway, D.A. (1994):**  
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids.  
*J. Virol.*, 68:4503-4505.
- 65- Halasz, C.L. (1994):**  
Treatment of common warts using the infrared coagulator.  
*J. Dermatol. Surg. Oncol.*, 20:252-255.
- 66- Harsch, A.; Marzilli, L.A.; Bunt, R.C.; Stubbe, J. and Vouros, P. (2000):**  
Accurate and rapid modeling of iron-bleomycin-induced DNA damage using tethered duplex oligonucleotides and electrospray ionization ion trap mass spectrometric analysis.  
*Nucleic Acids Research*, 9:1978-1985.
- 67- Hart, K.W.; Williams, O.M.; Thelwell, N.; Fiander, A.N.; Brown, T. and Lesek, k. (2001):**  
Novel method for detection, typing, and quantification of human papillomaviruses in clinical samples.  
*J. Clin. Microbiol.*, 39(9):3204-3212.
- 68- Harwood, C.A.; Spink, P.J.; Suretheran, T.; Leigh, I.M.; de Villers, E.M.; McGregor, J.M.; Proby, C.M. and Breuer, J. (1999):**  
Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts.  
*J. Clin. Microbiol.*, 37:3545-3555.
- 69- Hayes, M.E. and O'keefe, M.J. (1986):**  
Reduced dose of bleomycin in the treatment of recalcitrant warts.  
*J. Am. Acad. Dermatol.*, 15:1002-1006.
- 70- Hecht, S.M. (2000):**  
Bleomycin: new perspectives on the mechanism of action.  
*J. Nat. Prod.* 63:158-168.

- 71- Hengge, U.R.; Esser, S.; Schultewolter, T.; Behrendt, C.; Meyer, T. and Stockfleth, E. (2000):  
Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum.  
Br. J. Dermatol., 143:1026-1031.
- 72- Hirose, R.; Hori, M. and Shukuwa, T. (1994):  
Topical treatment of resistant warts with glutaraldehyde.  
J. Dermatol., 21:248-253.
- 73- Hirvikoski, P.; Tammi, R.; Kumpulainen, E.; Virtaniemi, J.; Parkkinen, J.P.; Tammi, M.; Johansson, R.; Agren, U.; Karhunen, J. and Kosma, V.M. (1999):  
Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma.  
Virchows Arch., 434: 37-44.
- 74- Holmes, C.E.; Abraham, A.T.; Hecht, S.M.; Florentz, C. and Giegé, R. (1996):  
Fe bleomycin as a probe of RNA conformation.  
Nucleic Acids Research, 27:3399-3406.
- 75- Howley, P.M. (1996):  
Papillomaviruses. In: Fields, B.N.; Knipe, D.M. and Howley, P.M. (eds.): Virology. Lippincott-Raven: Philadelphia, pp. 2045.
- 76- Hudson, A.L. (1976):  
Treatment of plantar warts with bleomycin .  
Arch. Dermatol., 112:1179.
- 77- Hulbert, J.C.; Grossman, J.E. and Cummings, K.B.(1983):  
Risk factors of anesthesia and surgery in bleomycin-treated patients.  
J. Urol., 130:163-164.
- 78- Israel, R.M. (1969):  
How I treat plantar warts.  
Post. Grad. Med. Pract. Derm., 215:1969-1971.

- 79- James, P.M.; Collier, M.P.; Hardcastle, A. and Lovegrove, S. (1993):**  
Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts.  
J. Am. Acad. Dermatol., 28:933-937.
- 80- Jennifer, F. (2000):**  
Verruca plantaris: past and present treatment.  
Connecticut Podiatric Medical Association, 9:20-23.
- 81- Jennifer, T.T.; Stephen, T.O.; Scott, S.T. and Laimonis, A.L. (2001):**  
Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes.  
J. Virol., 75:7564-7571.
- 82- Johnson, S.M.; Roberson, P.K. and Horn, T.D. (2001):**  
Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts.  
Arch. Dermatol., 137:451-455.
- 83- Karabulut, A.A. Sahin, S. and Eksioglu, M. (1997):**  
Is Cimetidine effective for nongenital warts: a double-blind placebo-controlled study.  
Arch. Dermatol., 133:533-534.
- 84- Kauvar, A.; McDaniel, D.H. and Geronemus, R.G. (1995):**  
Pulsed dye laser treatment of warts.  
Arch. Fam. Med., 4:1035-1040.
- 85- Kawana, Y.; Kawana, K. and Yoshikawa, H. (2001):**  
Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralizing epitope binds to the cell surface and enters the cytoplasm.  
J. Virol., 75:2331-2336.
- 86- Kent, H. (1969):**  
Warts and Ultrasound Therapy.  
Arch. Dermatol., 100:79-81.

- 87- Khan, M.A.; Tolleson, W.H.; Gangemi, J.D. and Pirisi, L.  
(1993):  
Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons.  
J. Virol., 67:3396-3403.
- 88- Kilkenny, M. and Marks, R. (1996):  
The descriptive epidemiology of warts in the community.  
Australas. J. Dermatol., 37:80-86.
- 89- Kirnbauer, R.; Hubbert, N.L. and Wheeler, C.M. (1994):  
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.  
J. Natl. Cancer inst., 86:494-499.
- 90- Kirnbauer, R.; Lenz, P. and Okun, M.M. (2003):  
Human papillomavirus. In: Bologna, J.L.; Jorizzo, J.L. and Rapini, R.B. (eds): Dermatology. Mosby, El Sevier, pp. 1217.
- 91- Kirnbauer, R.; Taub, J. and Grehnston, H. (1993):  
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.  
J. Virol., 67:6921-6936.
- 92- Kubeyinje, E.P. (1996):  
Evaluation of the efficacy and safety of 0.05% tretinoin cream in the treatment of plane warts in Arab children.  
J. Dermatol. Treat., 7:21-22.
- 93- Laffitte, F.; Chavoin, J.P. and Bonafe, J.L. (1985):  
Under heel foot warts.  
Dermatologica, 171:206-208.
- 94- Law, M.F.; Lowy, D.R.; Dvoretzky, I. and Howley, P.M.  
(1981):  
Mouse cell transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences.  
Proc. Natl. Acad. Sci. USA, 78:2727-2731.

- 95- Lazo, J.S.; Braun, I.D.; Labaree, D.C.; Schisselbauer, J.C.; Meandzija, B.; Newman, R.A. and Kennedy, K.A. (1989): Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance. *Cancer Res.*, 49:185-190.
- 96- Lee, S.; Kim, J.G. and Chun, S.I. (1980): Treatment of verruca plana with 5% 5-fluorouracil ointment. *Dermatologica*, 160:383-389.
- 97- Lowenthal, R.M. (1982): Normal infant after combination chemotherapy including tenoposide for Burkitt's lymphoma in pregnancy. *Med. Pediat. Oncol.*, 10:165-169.
- 98- Lowy, D.R. and Androphy, E.J. (1993): Warts. In: Fitzpatrick, T.B.; Eisen, A.Z.; Wolff, K.; Freedberg, I.M. and Austen, K.F. (eds): *Dermatology in general medicine*, 4<sup>th</sup> edition. New York, McGraw Hill Inc., pp. 2611.
- 99- Lowy, D.R. and Androphy, E.J. (2003): Warts. In: Freedberg, I.M.; Eisen, A.Z.; Wolff, K.; Freedberg, I.M. and Austen, K.F. (eds). *Dermatology in general medicine*, 6<sup>th</sup> edition. New York: McGraw-Hill Inc., pp. 2119.
- 100- Mahoney, J.M. (1996): Oral Cimetidine and the treatment of verrucae. *J. Am. Podiatr. Med. Assoc.*, 86:183-186.
- 101- Majewski, S. and Jablonska, S. (1997): Human papillomavirus-associated tumors of the skin and mucosa. *J. Am. Acad. Dermatol.*, 36:659-685.
- 102- Majewski, S.; Malejczyk, J.; Jablonska, S.; Misiewicz, J.; Rudnicka, L.; Obalek, S. and Orth, G. (1990): Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. *J. Am. Acad. Dermatol.*, 22:423-427.

- 103- Mantovani, F. and Banks, L. (1999):**  
The interaction between p53 and papillomaviruses.  
*Semin. Cancer Biol.*, 9:387-395.
- 104- Massing, A.M. and Epstein, W.L. (1963):**  
Natural history of warts.  
*Arch. Dermatol.*, 87:74-78.
- 105- Matsukura, T. and Sugase, M. (1995):**  
Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions.  
*Int. J. Cancer.*, 61:13-22.
- 106- McGlennen, R.C. (2000):**  
Human papillomavirus oncogenesis.  
*Clin. Lab. Med.*, 20:383-406.
- 107- McKee, P.H.; Wilkinson, J.D.; Black, M.M. and Whimster, I.W. (1981):**  
Carcinoma (epithelioma) cuniculatum: a clinicopathologic study of nineteen cases and review of the literature.  
*Histopathology*, 5:425-436.
- 108- Melton, J.L. and Rasmussen, J.E. (1991):**  
Clinical manifestations of human papillomavirus infection in non-genital sites.  
*Dermatologic Clinics*, 9:219-233.
- 109- Memar, O.M.; Arany, I. and Tyring, S.K. (1995):**  
Skin-associated lymphoid tissue in human immunodeficiency virus-1, human papillomavirus, and herpes simplex virus infections.  
*J. Investig. Dermatol.*, 105:99-104.
- 110- Miller, R.A. (1984):**  
Nail dystrophy following intralesional injections of bleomycin for a periungual wart.  
*Arch. Dermatol.*, 120:963-964.

- 111- Miori, L.; Vignini, M. and Rabbiosi, G. (1990):**  
Flagellate dermatitis after bleomycin.  
*Am. J. Dermatopathol.*, 12:598-602.
- 112- Morelli, A.E.; Belardi, G.; DiPaola, G.; Paredes, A. and Fainboim, L. (1994):**  
Cellular subsets and epithelial ICAM-1 and HLA-DR expression in human papillomavirus infection of the vulva.  
*Acta. Derm. Venereol.*, 74:45-50.
- 113- Morgan, M.A. and Hecht, S.M. (1994):**  
Iron(II) bleomycin-mediated degradation of a DNA-RNA heteroduplex.  
*Biochemistry*, 33:10286-10293.
- 114- Mosaad, I.; Younis, I. and Wahab, A.A. (1997):**  
An evaluation of a new method for bleomycin intralesional injection for the treatment of recalcitrant warts.  
*Med. J. Cairo Univ.*, 65:211-218.
- 115- Munkvad, M.; Genner, J.; Staberg, B. and Kongsholm, H. (1983):**  
Locally injected bleomycin in the treatment of warts.  
*Dermatologica*, 167:86-89.
- 116- Munn, S.E.; Higgins, E.; Marshall, M. and Clement, M. (1996):**  
A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts.  
*Br. J. Dermatol.*, 135:969-971.
- 117- Naor, D.; Nedvetzki, S.; Golan, I.; Melnik, L. and Faitelson, Y. (2002):**  
CD44 in cancer.  
*Crit. Rev. Clin. Lab. Sci.* 39:527-579.
- 118- Nemeth, A.J. and Reyes, B.A. (1990):**  
Copper vapor laser treatment of genital and body warts.  
*Laser Surg. Med.*, 15:52-53.

**119- Norris, D. A. (1990):**

Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets.  
J. Investig. Dermatol., 95:111-120.

**120- Olson, R.L. (1977):**

Plantar warts yield to DNA inhibitor.  
JAMA, 237:940-941.

**121- Parsad, D.; Saini, R. and Negi, K.S. (1999):**

Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts.  
Australas. J. Dermatol., 40:93-95.

**122- Parton, A.M. and Sommerville, R.G. (1994):**

The treatment of plantar verrucae by triggering cell-mediated immunity.  
J. Br. Pod. Med., 49:205-208.

**123- Penneys, N. (1999):**

Diseases caused by viruses. In: Elder, D.; Elienitsas, R.; Jaworsky, C. and Johnson, B. (eds). Histopathology of the skin 8<sup>th</sup> edition. Philadelphia: Lippincott-Raven, pp. 569.

**124- Pizzighella, S.; Pisoni, G.; Bevilacqua, F.; Vaona, A. and Palu, G. (1995):**

Simultaneous polymerase chain reaction detection and restriction typing for the diagnosis of human genital papillomavirus infection.  
J. Virol. Methods, 55:245-256.

**125- Popkin, J.D.; Hong, W.K. and Bromer, R.H. (1984):**

Induction bleomycin infusion in head and neck cancer.  
Am. J. Clin. Oncol., 7: 199-204.

**126- Raffles, A.; Williams, J.; Costeloe, K. and Clark, P. (1989):**

Transplacental effects of maternal cancer chemotherapy.  
Br. J. Obstet. Gynaecol., 96:1099-1100.

- 127- Rasmussen, K.A. (1958):**  
Verrucae plantares: symptomatology and epidemiology.  
Acta. Derm. Venereol., 38:142-146.
- 128- Reymann, F. (1969):**  
The sensitivity of plantar warts to Roentgen radiation.  
Acta. Derm. Venereol. (Stockh.), 49:171-175.
- 129- Rodeheffer, R.J.; Rommer, J.A.; Wigley, F. and Smith.  
C.R. (1983):**  
Controlled double-blind trial of nifedipine in the treatment of  
Raynaud's phenomenon  
N. Engl. J. Med., 308: 880-883.
- 130- Roden, R.B.; Lowy, D.R. and Schiller, J.T. (1997):**  
Papillomavirus is resistant to desiccation.  
J. Infect. Dis., 176:1076-1079.
- 131- Rogers, J.A. and O'Keef, E.J. (1987):**  
The biology and treatment of warts.  
Compr. Ther., 13:34-40.
- 132- Rogozinski, T.T.; Jablonska, S. and Jarzabek-Chorzelska,  
M. (1988):**  
Role of cell-mediated immunity in spontaneous regression of plane  
warts.  
Int. J. Dermatol., 27:322-326.
- 133- Saunders, N.A. and Frazer, I.H. (1998):**  
Simplifying the molecular mechanisms of human papillomavirus.  
Clin. Dermatol., 16:823-827.
- 134- Scheffner, M.; Romanczuk, H. and Munger, K. (1994):**  
Functions of human papillomavirus proteins.  
Curr. Top. Microbiol. Immunol., 186:83-99.
- 135- Schiller, J.T. and Lowy, D.R. (2001):**  
Papillomavirus-like particle vaccines: cervical cancer and beyond.  
Expert. Opin. Biol. Ther., 1:571-581.

- 136- Schiller, J.T. and Okun, M.M. (1996):**  
Papillomavirus vaccines: current status and future prospects.  
Adv. Dermatol., 11:355-381.
- 137- Schwartz, D.R.; Gregg, E.; Hoyt, D.G.; Klein, E.;  
Abernethy, J. and Lazo, J.S. (1999):**  
The neutral cysteine protease bleomycin hydrolase is essential for  
epidermal integrity and bleomycin resistance.  
Proc. Natl. Acad. Sci. USA., 96: 4680-4685.
- 138- Scott, M.; Nakagawa, M. and Moscicki, A.B. (2001):**  
Cell mediated immune response to human papillomavirus infection.  
Clin. Diagn. Lab. Immunol., 8: 209-220.
- 139- Senff, H.; Reinell, D. and Matthies, C. (1988):**  
Topical 5-fluorouracil solution in the treatment of warts: clinical  
experience and percutaneous absorption.  
Br. J. Dermatol., 118:609-614.
- 140- Shelley, W.B. and Shelly, E.D. (1991):**  
Intralesional bleomycin sulfate therapy for warts: a novel bifurcated  
needle puncture technique.  
Arch. Dermatol., 127: 234-236.
- 141- Shumack, P.H. and Haddock, M.J. (1979):**  
Bleomycin: an effective treatment of warts.  
Australas J. Dermatol., 20:41-42.
- 142- Shumer, M.S. and O'Keefe, J.E. (1983):**  
Bleomycin in the treatment of recalcitrant warts.  
J. Am. Acad. Dermatol., 9:91-96.
- 143- Siegfried, E.C. (1996):**  
Warts on children: An approach to therapy.  
Ped. Annals., 25:72-79.
- 144- Sinclair-Cieban, A.H.C. and Chalmers, D. (1959):**  
Evaluation of treatment of warts by hypnosis.  
Lancet., 45:15-21.

- 145- Skinner, R.B. (2003):**  
Imiquimod.  
Dermatol. Clin., 21:291-300.
- 146- Slade, H.B. (1998):**  
Cytokine induction and modifying the immune response to human papilloma virus with imiquimod.  
Eur. J. Dermatol., 8:13-16, 20-22.
- 147- Sollitto, R.J.; Napoli, R.C.; Gazivoda, P.L. and Hart, T.J. (1989):**  
A perspective study using bleomycin sulfate in the treatment of plantar verruca.  
J. Foot. Surg., 28:141-144.
- 148- Stadnyk, A.W. (1994):**  
Cytokine production by epithelial cells.  
FASEB J., 8:1041-1047.
- 149- Stanly, M.A. (2001):**  
Immunobiology of papillomavirus infection.  
J. Reproduct. Immunol., 52:45-59.
- 150- Stender, I.M.; Gluud, C.; Wulf, H.C. and Frog, H. (2000):**  
Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomized double-blind trial.  
Lancet, 355:963-966.
- 151- Stentella, P.; Frega, A.; Ciccarone, M.; Cipriano, L.; Tinari, A.; Tzantzoglou, S. and Pachi, A. (1998):**  
HPV and intraepithelial neoplasia recurrent lesions of the lower genital tract: assessment of the immune system.  
Eur. J. Gynaecol. Oncol., 19:466-469.
- 152- Stern, P. and Levine, N. (1992):**  
Controlled localized heat therapy in cutaneous warts.  
Arch. Dermatol., 128:945-948.

- 153- Stubenrauch, F. and Laimins, F.A. (1999):**  
Human papillomavirus life cycle: active and latent phases.  
*Semin. Cancer Biol.*, 9:379-386.
- 154- Stulberg, D.L. and Hutchinson, A.G. (2003):**  
Molluscum contagiosum and warts.  
*Am. Fam. Physician*, 67:1243-1244.
- 155- Susser, W.S.; Worth, D.L. and Kels, J.M. (1999):**  
Mucocutaneous reaction to chemotherapy.  
*J. Am. Acad. Dermatol.*, 40:367-398.
- 156- Takigawa, M.; Oku, T.; Ginoza, M.; Yamada, M.;  
Yamamoto, T. and Kobayashi, I. (1985):**  
Treatment of viral warts with pressure-sensitive adhesive tape  
containing bleomycin sulfate (letter).  
*Arch. Dermatol.*, 121:1108.
- 157- Tammi, R.; Paukkonen, K.; Wang, C.; Horsmanheimo, M.  
and Tammi, M. (1994):**  
Hyaluronan and CD44 in psoriatic skin. Intense staining for  
hyaluronan on dermal capillary loops and reduced expression of  
CD44 and hyaluronan in keratinocyte-leukocyte interfaces.  
*Arch. Dermatol. Res.*, 286:21-29.
- 158- Tan, O.T.; Hurwitz, R.M. and Stafford, T.J. (1993):**  
Pulsed dye laser treatment of recalcitrant verrucae: a preliminary  
report.  
*Laser Surg. Med.*, 13:127-137.
- 159- Templeton, F.S.; Solomon, R.A. and Swerlick, A.R. (1994):**  
Intradermal bleomycin injection into normal human skin.  
*Arch. Dermatol.*, 130:577-583.
- 160- Torre, D. C.; Losada, A. and Cruces, M.J (1997):**  
Keratoacanthoma centrifugum marginatum: treatment with  
intralesional bleomycin.  
*J. Am. Acad. Dermatol.*, 37:1010-1011.

- 161- Trissel, L.A.; Tramonte, S.M. and Grilley, B.J. (1991):  
Visual compatability of ondansetron hydrochloride with selected  
drugs during simulated Y-site injection.  
Am. J. Hosp. Pharm., 48:988-992.
- 162- Trus, B.L., Roden, R.B.S.; Greenstone, H.L.; Vrhel, M.;  
Schiller, J.T. and Booy, F.P. (1997):  
Novel structural features of bovine papillomavirus capsid revealed  
by a three-dimensional reconstruction to 9Å resolution.  
Nat. Struct. Biol., 4:413-420.
- 163- Tuhkanen, A.L.; Tammi, M.; Pelttari, A.; Agren, U. and  
Tammi, R. (1998):  
Ultrastructural analysis of human epidermal CD44 reveals  
preferential distribution on plasma membrane domains facing the  
hyaluronan-rich matrix pouches.  
J. Histochem. Cytochem., 46:241-248.
- 164- Tying, S.K.; Arany, I.; Stanley, M.A.; Tomai, M.A.;  
Miller, R.L.; Smith, M.H.; McDermott, D.J. and Slade,  
H.B. (1998):  
A randomized, controlled, molecular study of condylomata  
acuminata clearance during treatment with imiquimod.  
J. Infect. Dis., 178:551-555.
- 165- Umezawa, H.; Maeda, K.; Takeuchi, T. and Okami,  
Y. (1966):  
New antibiotics, bleomycin A and B.  
J. Antibiot., 19:200-209.
- 166- Unckell, F.; Streeck, R.E. and Sapp, M. (1997):  
Generation and neutralization of pseudovirions of human  
papillomavirus type 33.  
J. Virol., 71:2934-2939.

- 167- **Van der Kuyl, A.C.; van der Burg, R.; Zorgdrager, F.; Dekker, J.T.; Maas, J.; Noesel, C.J.; Goudsmit, J. and Cornelissen, M. (2002):**  
Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma.  
BMC Cancer, 2:21-23.
- 168- **Vanhooteghem, O.; Richert, B.; Brassinne, D.L. (2001):**  
Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin.  
Pediatr. Dermatol., 18:249-251.
- 169- **Vaughn, D.T. (1973):**  
Direct method versus underwater method in the treatment of plantar warts with ultrasound. A comparative study.  
Physical Therapy, 53:396-397.
- 170- **Viac, J.; Soler, C.; Chardonnet, Y.; Euvrard, S. and Schmitt, D. (1993):**  
Expression of immune associated surface antigens of keratinocytes in human papillomavirus-derived lesions.  
Immunobiology, 188:392-402.
- 171- **Villa, L.L.; Vieira, K.B.; Pei, X.F. and Schlegel, R. (1992):**  
Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18.  
Mol. Carcinog., 6:5-9.
- 172- **Von Gunten, C.F.; Roth, E.L. and Von Roenn, J.H. (1993):**  
Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin.  
Cancer, 72: 2004-2006.
- 173- **Von Ranset, M.; Kaplan, J.B. and Burk, R.D. (1992):**  
Phylogenetic classification of human papillomavirus: correlation with clinical manifestations.  
J. Gen. Virol., 73:2653-2660.

- 174- Wang, C.; Tammi, M. and Tammi, R. (1992):**  
Distribution of hyaluronan and its CD44 receptor in the epithelia of human skin appendages.  
*Histochemistry*, 98:105-112.
- 175- Wang, B.; Amerio, P. and Sauder, D.N. (1999):**  
Role of cytokines in epidermal Langerhans cell migration.  
*J. Leukoc. Biol.* 66:33-39.
- 176- Whitney, A.K. (1963):**  
Plantar verruectomy.  
*N. Eng. J. Podiat.*, 42:23-28.
- 177- Williams, S.D.; Brady, M.; Burnett, A., et al. (1999):**  
Adjuvant therapy of resected dysgerminoma with carboplatin and etoposide.  
*Proc. Soc. Gyn. Oncol.*, 28:114-116.
- 178- Woodworth, C.D.; Lichti, U.; Simpson, S.; Evans, C.H. and DiPaolo, J.A. (1992):**  
Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells.  
*Cancer. Res.*, 52:456-463.
- 179- Woodworth, C.D. and Simpson, S. (1993):**  
Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines.  
*Am. J. Pathol.*, 142:1544-1555.
- 180- Yasaka, N.; Furue, M. and Tamaki, K. (1995):**  
CD44 expression in normal human skin and skin tumors.  
*J. Dermatol.*, 22:88-94.
- 181- Yates, V.M.; Scott, M. and Carter, E.D. (1988):**  
Rupture of tendon after cryotherapy for hand warts.  
*Br. J. Dermatol.*, 297:1106.

**182- Ylitalo, N.; Bergstrom, T. and Gyllensten, U. (1995):**

Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization.  
J. Clin. Microbiol., 33:1822-1828.

**183- Young, R.; Jolley, D. and Marks, R. (1998):**

Comparison of the use of standardized diagnostic criteria and intuitive clinical diagnosis in the diagnosis of common viral warts (verrucae vulgaris).  
Arch. Dermatol., 134:1586-1589.

**184- Zhou, J.; Sun, X.Y.; Louis, K. and Frazer, I.H. (1994):**

Interaction of human papillomavirus (HPV) type 16 capsid protein with HPV DNA requires an intact L2 N-terminal sequence.  
J. Virol., 68:619-625.

**185- Zur Hausen, H. and de Viller, E.M. (1994):**

Human papillomaviruses.  
Annu. Rev. Microbiol., 48:427-447.